Dermata Therapeutics enters ATM equity facility for up to ~$1.16M

Dermata Therapeutics, Inc.

ATM Agreement with H.C. Wainwright for at-the-market issuance of common stock up to $1,157,761 aggregate market value.
Commission rate 3.0% of gross sales price; expense reimbursement up to $70,000 plus periodic due diligence fees.
Company has no obligation to sell; sales at prevailing market prices on Nasdaq under effective shelf registration statement.
Offering terminates upon sale of all shares or earlier termination by either party.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.